Danya Ben-Hail

Edward White

Li Wang Watsek

Sean McCutcheon

Anna Lee

Billal Jahangiri

Daniel Bronder

Li Watsek

Nicole Germino

Sara Nik

Soumit Roy

Srikripa Devarakonda

Yale Jen

- Curatis Holding AG reported **revenue of 5.2 million CHF** for the first half of 2025, marking a **14% year-over-year growth** compared to Curatis AG's revenue in the same period of 2024.  **[1108205_c88234f91ece45fca3987daf1ff384a5_0]** 
- The company recorded a **loss of 1.2 million CHF** for the period, primarily due to increased development expenses for its main product candidate, C-PTBE-01 (corticorelin).  **[1108205_c88234f91ece45fca3987daf1ff384a5_0]** 
- Curatis held a **positive Type B meeting with the US FDA on September 9, 2025**, to discuss the design of a **pivotal Phase 3 clinical trial** for C-PTBE-01, and has initiated the process to find global pharmaceutical partners for the product in Q3 2025.  **[1108205_c88234f91ece45fca3987daf1ff384a5_0]** **[1108205_c88234f91ece45fca3987daf1ff384a5_1]** 
- The company expanded its product portfolio through a partnership with Phoenix Labs, adding four products that generated approximately **5 million CHF in revenue in 2024**.  **[1108205_c88234f91ece45fca3987daf1ff384a5_0]** **[1108205_c88234f91ece45fca3987daf1ff384a5_2]** 
- Curatis Group anticipates **revenue growth in 2025** and aims to **reach break-even in 2026** through increased revenues and cost reductions.  **[1108205_c88234f91ece45fca3987daf1ff384a5_2]**

Curatis Reports H1 2025 Financials and Positive FDA Meeting for C-PTBE-01

- Curatis Holding AG reported **CHF 5.2 million** in revenue for the first half of 2025, marking a **14% growth** compared to the previous year, but recorded a loss of **CHF -1.2 million** primarily due to increased development expenses for C-PTBE-01.  **[1108205_7624a20fb37c45389565f085915c67a1_0]** 
- The company established a partnership with Phoenix Labs, adding **four products** that generated nearly **CHF 5 million** in revenue in 2024.  **[1108205_7624a20fb37c45389565f085915c67a1_0]** **[1108205_7624a20fb37c45389565f085915c67a1_2]** 
- Curatis held a **positive Type-B meeting** with the US FDA on **September 9, 2025**, to align on the design of the crucial Phase 3 clinical trial for its main drug candidate, C-PTBE-01 (Corticorelin).  **[1108205_7624a20fb37c45389565f085915c67a1_0]** **[1108205_7624a20fb37c45389565f085915c67a1_1]** 
- Curatis anticipates **revenue growth** for 2025 compared to 2024 and aims to achieve **break-even** in 2026, driven by new product introductions and the ongoing search for C-PTBE-01 partners.  **[1108205_7624a20fb37c45389565f085915c67a1_2]**

Curatis Reports H1 2025 Results and Positive FDA Meeting for C-PTBE-01

- Curatis reported **H1 2025 revenues of CHF 5.2m**, reflecting a **14% like-for-like year-over-year growth** in its distribution business, while incurring a **loss of CHF -1.2m** primarily due to increased development expenses for C-PTBE-01.  **[1108205_1c178612640c465c9835e32cc40bf82d_0]** 
- The company announced a **positive outcome** from its **Type B meeting with the US FDA on September 9, 2025**, regarding its lead product candidate, **C-PTBE-01 (corticorelin)**.  **[1108205_1c178612640c465c9835e32cc40bf82d_0]** **[1108205_1c178612640c465c9835e32cc40bf82d_1]** 
- A new partnership with Phoenix Labs, Ireland, added **four products** that generated approximately **CHF 5m in revenues in 2024**, which is expected to drive **revenue growth in 2025**.  **[1108205_1c178612640c465c9835e32cc40bf82d_0]** **[1108205_1c178612640c465c9835e32cc40bf82d_1]** 
- Curatis holds a **cash position of CHF 2.0m** and has set an objective to achieve a **break-even result in 2026**.  **[1108205_1c178612640c465c9835e32cc40bf82d_0]** **[1108205_1c178612640c465c9835e32cc40bf82d_1]**

CURIS (CRIS)